Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: May 7, 2026
Reporting Period: Quarterly period ended March 31, 2026
Context: The filing announces the release of financial results and an earnings presentation for the first quarter of 2026.
Key Financial Metrics
The provided Form 8-K text serves as a cover document referencing the press release (Exhibit 99.1) and earnings presentation (Exhibit 99.2). The filing text itself does not provide clear values for the following metrics:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt Levels
- Liquidity Position
Material Changes
The filing text does not contain specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for comparative financial analysis.
Guidance, Outlook, and Risks
Management Commentary: The Company released an earnings presentation (Exhibit 99.2) on May 7, 2026, which likely contains management commentary, outlook, and guidance. However, the specific content of this presentation is not included in the provided text.
Risks and Contingencies: No specific risks or contingencies are detailed in the Form 8-K text provided.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2026 revenue, net income, and cash flow figures.
- Examine Exhibit 99.2 (Earnings Presentation) for updated financial guidance and strategic outlook.
- Verify year-over-year performance metrics not present in this summary document.
- Check for any new risk factors or regulatory updates mentioned in the full press release.